Pharmafile Logo
Pharmafocus logo
Advanced Search

Dr Kai Lindevall re-appointed chief executive of Encorium

pharmafile | January 20, 2010 | Appointment | Research and Development |  Encorium, appointment, research and development 

Dr Kai Lindevall has been re-appointed chief executive of contract research organisation (CRO) Encorium, having held the post in 2008 before becoming president of Encorium’s Europe and Asia operations.

The last chief executive, David Ginsberg, left the firm last year to head up US division of Italian CRO Pierrel after it acquired Encorium’s US clinical trial operations.

Meanwhile, board member Shahab Fatheazam has also been named group chairman.

Advertisement

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025